Guilford, CT, United States of America

Shally Hsueh-Wen Wang

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Shally Hsueh-Wen Wang

Introduction

Shally Hsueh-Wen Wang is an accomplished inventor based in Guilford, CT (US). He has made significant contributions to the field of nucleic acid amplification, showcasing his expertise through innovative patent developments.

Latest Patents

Wang holds a patent for a "System and method for nucleic acid amplification." This invention describes a method for generating a population of amplified concatamer products. The process involves amplifying a template nucleic acid molecule using a first nucleic acid primer immobilized on a bead substrate and a second nucleic acid primer in solution. This method results in a population of substantially identical copies of the template nucleic acid molecule that are immobilized on the bead substrate. Furthermore, the population is amplified using a concatamer primer, which generates a population of immobilized concatamer products. Wang's innovative approach has the potential to enhance the efficiency of nucleic acid amplification techniques.

Career Highlights

Shally Hsueh-Wen Wang is associated with 454 Life Sciences Corporation, where he has been able to apply his knowledge and skills in a collaborative environment. His work has contributed to advancements in biotechnology and molecular biology.

Collaborations

Wang has worked alongside notable colleagues such as Brian Christopher Godwin and Priya Shanbhag, who have also contributed to the innovative projects at 454 Life Sciences Corporation.

Conclusion

Shally Hsueh-Wen Wang's contributions to nucleic acid amplification through his patent demonstrate his innovative spirit and dedication to advancing scientific research. His work continues to influence the field and inspire future developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…